Abstract 1142P
Background
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, causing a staggering death toll comparable to that of melanoma, despite its low propensity to metastasize (2-5%). However, until recently, cSCC has been perceived as a non-life-threatening tumor, and current clinical practices are suboptimal: clinical staging systems cannot consistently and reliably identify patients at high risk of metastasis, and they do not provide absolute metastatic risk. Therefore, decisions about follow-up schedules and treatment cannot be personalized.
Methods
We sought to improve the risk stratification as defined by the American Joint Committee on Cancer (AJCC) and the Brigham and Women's Hospital (BWH), by integrating a recently developed clinico-pathological (CP) model for metastatic risk in cSCC patients. We tried to identify patients at increased risk within the low-risk group (AJCC: T1-T2, BWH: T1-T2a) and in the high-risk group (AJCC: T3-T4, BWH: T2b-T3), We performed our analysis in a Dutch nested case-control cohort (n=390); binarized the 5-year metastatic risk into CP High-Risk and CP Low-Risk, by selecting thresholds based on likelihood ratios.
Results
In the low-risk group, the metastatic risk is 1.1% (AJCC) and 1.2% (BWH). Within this group CP High-Risk patients (AJCC: 2.6%, BWH=1.9%) have an increased risk (AJCC: 10.3%, BWH: 16.2%) and would be offered follow-up; but not the CP Low-Risk patients (AJCC: 97.4%, BWH=98.1%) with a decreased risk (AJCC: 0.9%, BWH: 0.98%). In the high-risk group, the metastatic risk is 5.7% (AJCC) and 12.8% (BWH). Within this group, CP High-Risk (AJCC:7.9 %, BWH=21.8%) have an increased risk (AJCC: 40.5%, BWH: 43.4%) and could be offered more intensive follow-up and treatment (e.g., adjuvant treatment).
Conclusions
Our data show that our risk model can enhance the AJCC and BWH staging systems, by refining the risk stratification in both the low-risk and high-risk groups. This has the potential to help clinicians, dermatologists, radiotherapists, and clinical oncologists make more personalized decisions about more intense follow-up schedules and treatment of their cSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Erasmus MC.
Funding
This study is funded by a PPP Allowance made available by Health∼Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships. In this case a public-private partnership between Erasmus MC and SkylineDx BV.
Disclosure
M. Wakkee: Financial Interests, Institutional, Funding: Sanofi, Regeneron; Financial Interests, Personal, Speaker, Consultant, Advisor: Regeneron. L. Pozza, S. Alex: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV. J. Dwarkasing: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV; Financial Interests, Personal, Stocks/Shares: SkylineDx BV. D. Bellomo: Financial Interests, Personal, Full or part-time Employment: SkylineDx BV; Financial Interests, Personal, Stocks/Shares: SkylineDx. All other authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13